(Q42215015)

English

Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer

scientific article published on 17 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

prostate cancer

1 reference

based on heuristic

6

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

author name string

Ari Adamy

1

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

David S Yee

2

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Kazuhito Matsushita

3

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Alexandra Maschino

4

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Angel Cronin

5

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Bertrand Guillonneau

7

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Peter T Scardino

8

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

James A Eastham

9

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

language of work or name

0 references

publication date

17 December 2010

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Journal of Urology

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

185

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

2

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

477-482

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Insignificant prostate cancer and active surveillance: from definition to clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

A multi-institutional evaluation of active surveillance for low risk prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Active surveillance for the management of prostate cancer in a contemporary cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Active surveillance for early-stage prostate cancer: review of the current literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Contemporary trends in low risk prostate cancer: risk assessment and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Active surveillance for prostate cancer with selective delayed definitive therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

An analysis of men with clinically localized prostate cancer who deferred definitive therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

26 October 2017

Prostate-specific antigen levels as a predictor of lethal prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

29 May 2018

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

17 August 2018

Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

17 August 2018

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3417207

17 August 2018

Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/21167529

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Counseling Men With Prostate Cancer: A Nomogram for Predicting the Presence of Small, Moderately Differentiated, Confined Tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21167529

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21167529

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

1 reference

https://pubmed.ncbi.nlm.nih.gov/21167529

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance

1 reference

https://pubmed.ncbi.nlm.nih.gov/21167529

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.JURO.2010.09.095

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42215015&oldid=1667440549"